Patents by Inventor David R. Buckler
David R. Buckler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210204531Abstract: A genetically modified mouse is provided, wherein the mouse is incapable of rearranging and expressing an endogenous mouse immunoglobulin light chain variable sequence, wherein the mouse expresses only one or two human light chain variable domains encoded by human immunoglobulin sequences operably linked to the mouse kappa (?) constant gene at the endogenous mouse ? locus, wherein the mouse expresses a reverse chimeric antibody having a light chain variable domain derived from one of only two human light chain variable region gene segments and a mouse ? constant domain, and a human heavy chain variable domain and a mouse heavy chain constant domain, from an endogenous mouse heavy chain locus. Bispecific epitope-binding proteins that are fully human are provided, comprising two different heavy chains that associate with an identical light chain that comprises a variable domain derived from one of two different human light chain variable region gene segments.Type: ApplicationFiled: March 23, 2021Publication date: July 8, 2021Applicant: Regeneron Pharmaceuticals, Inc.Inventors: John McWhirter, Lynn Macdonald, Sean Stevens, David R. Buckler, Andrew J. Murphy
-
Patent number: 10986820Abstract: A genetically modified mouse is provided, wherein the mouse is incapable of rearranging and expressing an endogenous mouse immunoglobulin light chain variable sequence, wherein the mouse expresses only one or two human light chain variable domains encoded by human immunoglobulin sequences operably linked to the mouse kappa (?) constant gene at the endogenous mouse ? locus, wherein the mouse expresses a reverse chimeric antibody having a light chain variable domain derived from one of only two human light chain variable region gene segments and a mouse ? constant domain, and a human heavy chain variable domain and a mouse heavy chain constant domain, from an endogenous mouse heavy chain locus. Bispecific epitope-binding proteins that are fully human are provided, comprising two different heavy chains that associate with an identical light chain that comprises a variable domain derived from one of two different human light chain variable region gene segments.Type: GrantFiled: October 19, 2018Date of Patent: April 27, 2021Assignee: Regeneron Pharmaceuticals, Inc.Inventors: John McWhirter, Lynn Macdonald, Sean Stevens, David R. Buckler, Andrew J. Murphy
-
Patent number: 10519240Abstract: The present invention provides agonists of FGF21 signaling. In particular, the present invention provides FGF21 receptor (FGF21R) agonists that are capable of simultaneously binding ?Klotho (KLB) and/or FGFR1c to mimic the signaling activity of FGF21. The present invention also provides anti-FGF21 and anti-KLB/FGFR1c antibodies and antigen-binding fragments thereof. Also provided are methods of treating various metabolic disorders by administering the FGF21R agonists and/or anti-FGF21 antibodies to a subject in need thereof.Type: GrantFiled: March 25, 2015Date of Patent: December 31, 2019Assignee: Regeneron Pharmaceuticals, Inc.Inventors: George D. Yancopoulos, Andrew J. Murphy, Jesper Gromada, David R. Buckler, Kihwa Kang
-
Patent number: 10259870Abstract: The present invention provides antibodies that bind to ANGPTL8 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human ANGPTL8 with high affinity. The antibodies of the invention may be fully human antibodies. The antibodies of the invention are useful for the treatment of various diseases or disorders characterized in part by elevated blood triglyceride levels.Type: GrantFiled: August 4, 2016Date of Patent: April 16, 2019Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Viktoria Gusarova, Jesper Gromada, Andrew J. Murphy, David R. Buckler
-
Publication number: 20190090462Abstract: A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided.Type: ApplicationFiled: October 12, 2018Publication date: March 28, 2019Inventors: Robert Babb, John McWhirter, Lynn Macdonald, Sean Stevens, Samuel Davis, David R. Buckler, Karolina A. Meagher, Andrew J. Murphy, Natasha Levenkova
-
Publication number: 20190040123Abstract: A genetically modified mouse is provided, wherein the mouse is incapable of rearranging and expressing an endogenous mouse immunoglobulin light chain variable sequence, wherein the mouse expresses only one or two human light chain variable domains encoded by human immunoglobulin sequences operably linked to the mouse kappa (?) constant gene at the endogenous mouse ? locus, wherein the mouse expresses a reverse chimeric antibody having a light chain variable domain derived from one of only two human light chain variable region gene segments and a mouse ? constant domain, and a human heavy chain variable domain and a mouse heavy chain constant domain, from an endogenous mouse heavy chain locus. Bispecific epitope-binding proteins that are fully human are provided, comprising two different heavy chains that associate with an identical light chain that comprises a variable domain derived from one of two different human light chain variable region gene segments.Type: ApplicationFiled: October 19, 2018Publication date: February 7, 2019Inventors: John McWhirter, Lynn Macdonald, Sean Stevens, David R. Buckler, Andrew J. Murphy
-
Publication number: 20190021295Abstract: A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided.Type: ApplicationFiled: February 8, 2018Publication date: January 24, 2019Inventors: Robert Babb, John McWhirter, Lynn Macdonald, Sean Stevens, Samuel Davis, David R. Buckler, Karolina A. Meagher, Andrew J. Murphy, Natasha Levenkova
-
Patent number: 10143186Abstract: A genetically modified mouse is provided, wherein the mouse is incapable of rearranging and expressing an endogenous mouse immunoglobulin light chain variable sequence, wherein the mouse expresses only one or two human light chain variable domains encoded by human immunoglobulin sequences operably linked to the mouse kappa (?) constant gene at the endogenous mouse ? locus, wherein the mouse expresses a reverse chimeric antibody having a light chain variable domain derived from one of only two human light chain variable region gene segments and a mouse ? constant domain, and a human heavy chain variable domain and a mouse heavy chain constant domain, from an endogenous mouse heavy chain locus. Bispecific epitope-binding proteins that are fully human are provided, comprising two different heavy chains that associate with an identical light chain that comprises a variable domain derived from one of two different human light chain variable region gene segments.Type: GrantFiled: February 8, 2011Date of Patent: December 4, 2018Assignee: Regeneron Pharmaceuticals, Inc.Inventors: John McWhirter, Lynn Macdonald, Sean Stevens, David R. Buckler, Andrew J. Murphy
-
Publication number: 20170174769Abstract: The present invention provides agonists of FGF21 signaling. In particular, the present invention provides FGF21 receptor (FGF21R) agonists that are capable of simultaneously binding ?Klotho (KLB) and/or FGFR1c to mimic the signaling activity of FGF21. The present invention also provides anti-FGF21 and anti-KLB/FGFR1c antibodies and antigen-binding fragments thereof. Also provided are methods of treating various metabolic disorders by administering the FGF21R agonists and/or anti-FGF21 antibodies to a subject in need thereof.Type: ApplicationFiled: March 25, 2015Publication date: June 22, 2017Inventors: George D. YANCOPPULOS, Andrew J. MURPHY, Jesper GROMADA, David R. BUCKLER, Kihwa KANG
-
Publication number: 20170037124Abstract: The present invention provides antibodies that bind to ANGPTL8 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human ANGPTL8 with high affinity. The antibodies of the invention may be fully human antibodies. The antibodies of the invention are useful for the treatment of various diseases or disorders characterized in part by elevated blood triglyceride levels.Type: ApplicationFiled: August 4, 2016Publication date: February 9, 2017Inventors: Viktoria Gusarova, Jesper Gromada, Andrew J. Murphy, David R. Buckler
-
Patent number: 9386938Abstract: Diagnostic compositions and methods for imaging and/or assessing collagen are described. The diagnostic compositions can include collagen binding peptides.Type: GrantFiled: September 12, 2011Date of Patent: July 12, 2016Assignee: Collagen Medical, LLCInventors: Peter D. Caravan, Andrew Kolodziej, Zhaoda Zhang, Stephane Dumas, Biplab Kumar Das, Vincent Jacques, Richard Looby, Steffi K. Koerner, Wei-Chuan Sun, David R. Buckler, Aida Abujoub, Aaron K. Sato
-
Publication number: 20150313193Abstract: A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making light chain variable regions in mice, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, are provided.Type: ApplicationFiled: April 6, 2015Publication date: November 5, 2015Inventors: John McWhirter, Lynn Macdonald, Sean Stevens, Samuel Davis, David R. Buckler, Karolina A. Hosiawa, Andrew J. Murphy
-
Publication number: 20130302836Abstract: A genetically modified mouse is provided, wherein the mouse is incapable of rearranging and expressing an endogenous mouse immunoglobulin light chain variable sequence, wherein the mouse expresses only one or two human light chain variable domains encoded by human immunoglobulin sequences operably linked to the mouse kappa (?) constant gene at the endogenous mouse ? locus, wherein the mouse expresses a reverse chimeric antibody having a light chain variable domain derived from one of only two human light chain variable region gene segments and a mouse ? constant domain, and a human heavy chain variable domain and a mouse heavy chain constant domain, from an endogenous mouse heavy chain locus. Bispecific epitope-binding proteins that are fully human are provided, comprising two different heavy chains that associate with an identical light chain that comprises a variable domain derived from one of two different human light chain variable region gene segments.Type: ApplicationFiled: July 23, 2013Publication date: November 14, 2013Inventors: John McWhirter, Lynn Macdonald, Sean Stevens, Samuel Davis, David R. Buckler, Andrew J. Murphy
-
Publication number: 20130198879Abstract: Mice, tissues, cells, and genetic material are provided that comprise a humanized heavy chain immunoglobulin locus, a humanized light chain locus that expresses a universal light chain, and a gene encoding an ADAM6 or ortholog or homolog or functional fragment thereof. Mice are provided that express humanized heavy chains comprising human variable domains, and that express humanized light chains comprising human variable domains wherein the light chains are derived from no more than one, or no more than two, light chain V and J or rearranged V/J sequences. Fertile male mice that express antibodies with universal light chains and humanized heavy chains are provided. Methods and compositions for making bispecific binding proteins are provided.Type: ApplicationFiled: August 3, 2012Publication date: August 1, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventors: John McWhirter, Lynn MacDonald, Sean Stevens, Samuel Davis, David R. Buckler, Karolina A. Hosiawa, Andrew J. Murphy
-
Publication number: 20130045492Abstract: A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided.Type: ApplicationFiled: June 5, 2012Publication date: February 21, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Robert Babb, John McWhirter, Lynn MacDonald, Sean Stevens, Samuel Davis, David R. Buckler, Karolina A. Hosiawa, Andrew J. Murphy
-
Publication number: 20120192300Abstract: A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making light chain variable regions in mice, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, are provided.Type: ApplicationFiled: March 6, 2012Publication date: July 26, 2012Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Robert Babb, John McWhirter, Lynn MacDonald, Sean Stevens, Samuel Davis, David R. Buckler, Karolina A. Hosiawa, Andrew J. Murphy
-
Publication number: 20120114557Abstract: Diagnostic compositions and methods for imaging and/or assessing collagen are described. The diagnostic compositions can include collagen binding peptides.Type: ApplicationFiled: September 12, 2011Publication date: May 10, 2012Applicant: COLLAGEN MEDICAL, LLCInventors: Peter D. Caravan, Andrew Kolodziej, Zhaoda Zhang, Stephane Dumas, Biplab Kumar Das, Vincent Jacques, Richard Looby, Steffi K. Koerner, Wei-Chuan Sun, David R. Buckler, Aida Abujoub, Aaron K. Sato
-
Publication number: 20120021409Abstract: A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making light chain variable regions in mice, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, are provided.Type: ApplicationFiled: April 25, 2011Publication date: January 26, 2012Applicant: Regeneron Pharmaceuticals, Inc.Inventors: John McWhirter, Lynn MacDonald, Sean Stevens, Samuel Davis, David R. Buckler, Karolina A. Hosiawa, Andrew J. Murphy
-
Patent number: 8034898Abstract: Diagnostic compositions and methods for imaging and/or assessing collagen are described. The diagnostic compositions can include collagen binding peptides.Type: GrantFiled: December 29, 2006Date of Patent: October 11, 2011Assignee: Collagen Medical, LLCInventors: Peter D. Caravan, Andrew Kolodziej, Zhaoda Zhang, Stephane Dumas, Biplab Kumar Das, Vincent Jacques, Richard Looby, Steffi K. Koerner, Wei-Chuan Sun, David R. Buckler, Aida Abujoub, Aaron K. Sato
-
Publication number: 20110195454Abstract: A genetically modified mouse is provided, wherein the mouse is incapable of rearranging and expressing an endogenous mouse immunoglobulin light chain variable sequence, wherein the mouse expresses only one or two human light chain variable domains encoded by human immunoglobulin sequences operably linked to the mouse kappa (?) constant gene at the endogenous mouse ? locus, wherein the mouse expresses a reverse chimeric antibody having a light chain variable domain derived from one of only two human light chain variable region gene segments and a mouse ? constant domain, and a human heavy chain variable domain and a mouse heavy chain constant domain, from an endogenous mouse heavy chain locus. Bispecific epitope-binding proteins that are fully human are provided, comprising two different heavy chains that associate with an identical light chain that comprises a variable domain derived from one of two different human light chain variable region gene segments.Type: ApplicationFiled: February 8, 2011Publication date: August 11, 2011Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: JOHN MCWHIRTER, LYNN MACDONALD, SEAN STEVENS, SAMUEL DAVIS, DAVID R. BUCKLER, ANDREW J. MURPHY